A once abandoned drug compound shows an ability to rebuild organs damaged by illness and injury.Read more
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne...Read more
Novo Biosciences Inc. has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine...Read more
Looking beyond stem cells and tissue engineering: What if lost and damaged tissues and organs could be regenerated simply by taking a drug?
While stem cell and tissue engineering approaches may ultimately deliver on their clinical promise, small molecules that control innate regeneration mechanisms offer a less complex and more economical path to realizing regenerative medicine’s...Read more
US researchers claim to have identified a groundbreaking drug that could restore heart muscle function following a heart attack. A new study describes how MSI-1436, a naturally occurring compound, regenerates heart muscle tissue in zebrafish and...Read more
A federal patent has been awarded to scientists at Novo Biosciences, a step that will allow research to proceed on a molecule that shows promise in helping heart tissue regenerate after a heart attack.Read more